Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Average Rating of “Buy” from Brokerages
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) has been assigned an average recommendation of “Buy” from the seven research firms that are covering the stock, Marketbeat.com reports. One ...
Bleakley Financial Group LLC Makes New $323,000 Investment in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
Bleakley Financial Group LLC bought a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) in the fourth quarter, Holdings Channel reports. The firm bought 5,825 shares ...
Oppenheimer lifts Tarsus stock target, impressed by execution and ocular rosacea potential
Oppenheimer updated its outlook on Tarsus Pharmaceuticals (NASDAQ:TARS), a $1.8 billion market cap biotechnology company, increasing the price target to $72.00 from the previous $65.00 while ...
Tarsus Pharmaceuticals reshuffles board, appoints new committee chair
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), a $1.78 billion market cap company specializing in biological products, announced changes to its Board of Directors and committee assignments, according to ...
Tarsus to Participate in Upcoming Investor Conferences
IRVINE, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: TARS), today announced that management will participate in ...
Business Insider1mon
Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY® and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care
Jan. 13, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today provided an update on the Company’s key priorities for 2025, including plans to advance TP-04 for the ...
Nasdaq29d
Tarsus Pharmaceuticals Advances TP-04 for Ocular Rosacea Treatment, Phase 2 Study Set for 2025
Tarsus Pharmaceuticals, Inc. has announced plans to advance TP-04, an investigational ophthalmic gel formulation of lotilaner, for the treatment of Ocular Rosacea, a significant but currently ...
The Most Common Eyelid Disease You’ve Never Heard of Is Caused by Tiny Mites
Dealing with red, itchy eyelids? The culprit could be a common mite. This article is sponsored by XDEMVY. Dr. Watson is a paid consultant for Tarsus Pharmaceuticals.
A Glimpse Into The Expert Outlook On Tarsus Pharmaceuticals Through 4 Analysts
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $60.0, a high estimate of $72.00, and a low estimate of $41.00. Surpassing the previous average ...
Forbes12d
Tarsus Pharmaceuticals
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03 ...
Barclays Sticks to Their Buy Rating for Tarsus Pharmaceuticals (TARS)
Barclays analyst Balaji Prasad maintained a Buy rating on Tarsus Pharmaceuticals (TARS – Research Report) today and set a price target of ...
CNN4y
Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03 ...